

Benoit I Giasson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8613694/publications.pdf>

Version: 2024-02-01

153
papers

15,775
citations

17440

63
h-index

17592

121
g-index

156
all docs

156
docs citations

156
times ranked

12032
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuronal α -Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α -Synuclein. <i>Neuron</i> , 2002, 34, 521-533.	8.1	1,094
2	A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α -Synuclein Is Essential for Filament Assembly. <i>Journal of Biological Chemistry</i> , 2001, 276, 2380-2386.	3.4	865
3	Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein. <i>Science</i> , 2003, 300, 636-640.	12.6	791
4	Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α -synuclein. <i>Annals of Neurology</i> , 1998, 44, 415-422.	5.3	633
5	Lewy Bodies Contain Altered α -Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. <i>American Journal of Pathology</i> , 1998, 153, 1365-1370.	3.8	484
6	Mutant and Wild Type Human α -Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro. <i>Journal of Biological Chemistry</i> , 1999, 274, 7619-7622.	3.4	478
7	Induction of α -Synuclein Aggregation by Intracellular Nitroative Insult. <i>Journal of Neuroscience</i> , 2001, 21, 8053-8061.	3.6	412
8	The E46K Mutation in α -Synuclein Increases Amyloid Fibril Formation. <i>Journal of Biological Chemistry</i> , 2005, 280, 7800-7807.	3.4	327
9	Role of α -Synuclein Carboxy-Terminus on Fibril Formation in Vitro. <i>Biochemistry</i> , 2003, 42, 8530-8540.	2.5	314
10	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. <i>Annals of Neurology</i> , 2002, 52, 205-210.	5.3	300
11	Mouse Model of Multiple System Atrophy α -Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration. <i>Neuron</i> , 2005, 45, 847-859.	8.1	277
12	Intramuscular injection of α -synuclein induces CNS α -synuclein pathology and a rapid-onset motor phenotype in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10732-10737.	7.1	277
13	The relationship between oxidative/nitroative stress and pathological inclusions in Alzheimer's and Parkinson's diseases ^{1,2} 11 Guest Editors: Mark A. Smith and George Perry 22 This article is part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease." The full list of papers may be found on the homepage of the journal.. <i>Free Radical Biology and Medicine</i> , 2002, 33, 1264-1275.	2.9	252
14	Reversible Inhibition of α -Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations*. <i>Journal of Biological Chemistry</i> , 2005, 280, 21212-21219.	3.4	248
15	Concurrence of α -synuclein and tau brain pathology in the Contursi kindred. <i>Acta Neuropathologica</i> , 2002, 104, 7-11.	7.7	247
16	Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated α -synuclein gene mutations precede central nervous system changes. <i>Human Molecular Genetics</i> , 2010, 19, 1633-1650.	2.9	237
17	A Precipitating Role for Truncated α -Synuclein and the Proteasome in α -Synuclein Aggregation. <i>Journal of Biological Chemistry</i> , 2005, 280, 22670-22678.	3.4	229
18	Biochemical and pathological characterization of Lrrk2. <i>Annals of Neurology</i> , 2006, 59, 315-322.	5.3	229

#	ARTICLE	IF	CITATIONS
19	Are Ubiquitination Pathways Central to Parkinson's Disease?. <i>Cell</i> , 2003, 114, 1-8.	28.9	216
20	Î±-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. <i>Neurobiology of Aging</i> , 2008, 29, 739-752.	3.1	202
21	A panel of epitope-specific antibodies detects protein domains distributed throughout human ?-synuclein in lewy bodies of Parkinson's disease. , 2000, 59, 528-533.		197
22	Chaperone-like activity of synucleins. <i>FEBS Letters</i> , 2000, 474, 116-119.	2.8	196
23	Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by Î± ¹ -, Î± ² -, and Î± ³ -Synuclein Neuropathology. <i>American Journal of Pathology</i> , 2000, 157, 361-368.	3.8	190
24	MAPT mutations, tauopathy, and mechanisms of neurodegeneration. <i>Laboratory Investigation</i> , 2019, 99, 912-928.	3.7	190
25	Oxidative post-translational modifications of Î±-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2001, 76, 637-640.	3.9	184
26	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. <i>Acta Neuropathologica</i> , 2016, 131, 49-73.	7.7	179
27	More than just two peas in a pod: common amyloidogenic properties of tau and Î±-synuclein in neurodegenerative diseases. <i>Trends in Neurosciences</i> , 2004, 27, 129-134.	8.6	177
28	Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of Î±-Synuclein. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 402-416.	1.7	176
29	Molecular mechanisms of Î±-synuclein neurodegeneration. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 616-624.	3.8	174
30	Induction of Intracellular Tau Aggregation Is Promoted by Î±-Synuclein Seeds and Provides Novel Insights into the Hyperphosphorylation of Tau. <i>Journal of Neuroscience</i> , 2011, 31, 7604-7618.	3.6	165
31	A Cellular System that Degrades Misfolded Proteins and Protects against Neurodegeneration. <i>Molecular Cell</i> , 2014, 55, 15-30.	9.7	157
32	Fibrillization of ?-synuclein and tau in familial Parkinson's disease caused by the A53T ?-synuclein mutation. <i>Experimental Neurology</i> , 2004, 187, 279-288.	4.1	151
33	Distinct cleavage patterns of normal and pathologic forms of Î±-synuclein by calpain I in vitro. <i>Journal of Neurochemistry</i> , 2003, 86, 836-847.	3.9	147
34	Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. <i>Cancer</i> , 2000, 88, 2154-2163.	4.1	145
35	Snaring the Function of Î±-Synuclein. <i>Cell</i> , 2005, 123, 359-361.	28.9	143
36	Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of Î±-Synuclein Permutations in Multiple System Atrophy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 830-841.	1.7	135

#	ARTICLE	IF	CITATIONS
37	Ubiquitination of α -Synuclein Is Not Required for Formation of Pathological Inclusions in α -Synucleinopathies. <i>American Journal of Pathology</i> , 2003, 163, 91-100.	3.8	129
38	Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. <i>FASEB Journal</i> , 2006, 20, 2000-2008.	0.5	126
39	A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. <i>Journal of Neurochemistry</i> , 2003, 86, 1359-1368.	3.9	124
40	Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited α -synuclein accumulation and age-dependent sensorimotor deficits. <i>Human Molecular Genetics</i> , 2013, 22, 2067-2082.	2.9	124
41	Specificity and Regulation of Casein Kinase-Mediated Phosphorylation of α -Synuclein. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2008, PAP, 402-16.	1.7	116
42	E46K Human α -Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment. <i>Journal of Biological Chemistry</i> , 2011, 286, 35104-35118.	3.4	115
43	Brain Injection of α -Synuclein Induces Multiple Proteinopathies, Gliosis, and a Neuronal Injury Marker. <i>Journal of Neuroscience</i> , 2014, 34, 12368-12378.	3.6	115
44	α -Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. <i>Acta Neuropathologica</i> , 2019, 138, 1-21.	7.7	109
45	Cleavage of α -Synuclein by Calpain: A Potential Role in Degradation of Fibrillized and Nitrated Species of α -Synuclein. <i>Biochemistry</i> , 2005, 44, 7818-7829.	2.5	107
46	Divergent effects of the H50Q and G51D <i>SNCA</i> mutations on the aggregation of α -synuclein. <i>Journal of Neurochemistry</i> , 2014, 131, 859-867.	3.9	104
47	Inflammatory pre-conditioning restricts the seeded induction of α -synuclein pathology in wild type mice. <i>Molecular Neurodegeneration</i> , 2017, 12, 1.	10.8	104
48	Amyloidogenic α -synuclein seeds do not invariably induce rapid, widespread pathology in mice. <i>Acta Neuropathologica</i> , 2014, 127, 645-665.	7.7	103
49	Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. <i>Journal of Biological Chemistry</i> , 2018, 293, 2408-2421.	3.4	103
50	The emerging role of α -synuclein truncation in aggregation and disease. <i>Journal of Biological Chemistry</i> , 2020, 295, 10224-10244.	3.4	99
51	Thinking laterally about neurodegenerative proteinopathies. <i>Journal of Clinical Investigation</i> , 2013, 123, 1847-1855.	8.2	98
52	Interactions of Amyloidogenic Proteins. <i>NeuroMolecular Medicine</i> , 2003, 4, 49-58.	3.4	91
53	Don't Phos Over Tau: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies. <i>Molecular Neurodegeneration</i> , 2021, 16, 37.	10.8	89
54	Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. <i>Brain</i> , 2014, 137, 3235-3247.	7.6	88

#	ARTICLE	IF	CITATIONS
55	The major targets of acute norovirus infection are immune cells in the gut-associated lymphoid tissue. <i>Nature Microbiology</i> , 2017, 2, 1586-1591.	13.3	86
56	LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. <i>Acta Neuropathologica</i> , 2013, 126, 809-827.	7.7	85
57	Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 473-477.	2.1	84
58	Characterization of Hydrophobic Residue Requirements for α -Synuclein Fibrillization. <i>Biochemistry</i> , 2009, 48, 9427-9436.	2.5	82
59	Induction of CNS α -synuclein pathology by fibrillar and non-amyloidogenic recombinant α -synuclein. <i>Acta Neuropathologica Communications</i> , 2013, 1, 38.	5.2	78
60	A novel, high efficiency cellular model of fibrillar α -synuclein inclusions and the examination of mutations that inhibit amyloid formation. <i>Journal of Neurochemistry</i> , 2010, 113, 374-388.	3.9	75
61	Neurofurans, Novel Indices of Oxidant Stress Derived from Docosahexaenoic Acid. <i>Journal of Biological Chemistry</i> , 2008, 283, 6-16.	3.4	73
62	Characterization of kinases involved in the phosphorylation of aggregated α -synuclein. <i>Journal of Neuroscience Research</i> , 2011, 89, 231-247.	2.9	73
63	Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α -Synuclein Fibrils. <i>Journal of Virology</i> , 2017, 91, .	3.4	73
64	Characterization of antibodies that selectively detect α -synuclein in pathological inclusions. <i>Acta Neuropathologica</i> , 2008, 116, 37-46.	7.7	72
65	Prion-like Spreading in Tauopathies. <i>Biological Psychiatry</i> , 2018, 83, 337-346.	1.3	70
66	A new link between pesticides and Parkinson's disease. <i>Nature Neuroscience</i> , 2000, 3, 1227-1228.	14.8	67
67	Physiological C-terminal truncation of α -synuclein potentiates the prion-like formation of pathological inclusions. <i>Journal of Biological Chemistry</i> , 2018, 293, 18914-18932.	3.4	64
68	Conformational templating of α -synuclein aggregates in neuronal-glia cultures. <i>Molecular Neurodegeneration</i> , 2013, 8, 17.	10.8	61
69	Determinants of seeding and spreading of α -synuclein pathology in the brain. <i>Science Advances</i> , 2020, 6, .	10.3	61
70	Proteolysis of α -synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. <i>Journal of Neurochemistry</i> , 2017, 140, 662-678.	3.9	59
71	The Environmental Toxin Arsenite Induces Tau Hyperphosphorylation. <i>Biochemistry</i> , 2002, 41, 15376-15387.	2.5	58
72	Multiple system atrophy-associated oligodendroglial protein p25 α stimulates formation of novel α -synuclein strain with enhanced neurodegenerative potential. <i>Acta Neuropathologica</i> , 2021, 142, 87-115.	7.7	55

#	ARTICLE	IF	CITATIONS
73	Role of Oxidative Damage in Protein Aggregation Associated with Parkinson's Disease and Related Disorders. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 672-684.	5.4	52
74	Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 88.	5.2	52
75	Propagation of A β , tau and α -synuclein pathology between experimental models and human reality: prions, propagons and propaganda. <i>Acta Neuropathologica</i> , 2016, 131, 1-3.	7.7	51
76	Intrastriatal injection of α -synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. <i>Molecular Neurodegeneration</i> , 2017, 12, 40.	10.8	51
77	TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2018, 215, 2247-2264.	8.5	50
78	Prominent Perikaryal Expression of α - and β -Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons. <i>Experimental Neurology</i> , 2001, 172, 354-362.	4.1	49
79	Unique α -synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. <i>Acta Neuropathologica Communications</i> , 2019, 7, 142.	5.2	49
80	Mutations in <i>LRRK2</i> as a Cause of Parkinson's Disease. <i>NeuroSignals</i> , 2008, 16, 99-105.	0.9	48
81	rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. <i>Journal of Experimental Medicine</i> , 2019, 216, 539-555.	8.5	48
82	Novel antibodies to phosphorylated α -synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes. <i>Acta Neuropathologica Communications</i> , 2016, 4, 80.	5.2	47
83	Endogenous oligodendroglial alpha-synuclein and TPPP/p25 α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. <i>Acta Neuropathologica</i> , 2019, 138, 415-441.	7.7	45
84	A novel panel of α -synuclein antibodies reveal distinctive staining profiles in synucleinopathies. <i>PLoS ONE</i> , 2017, 12, e0184731.	2.5	45
85	Clinical and pathological characteristics of patients with Leucine-rich repeat kinase-2 mutations. <i>Movement Disorders</i> , 2009, 24, 32-39.	3.9	44
86	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	3.4	40
87	Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. <i>Acta Neuropathologica Communications</i> , 2017, 5, 58.	5.2	39
88	Unbiased screen reveals ubiquitin-1 and -2 highly associated with huntingtin inclusions. <i>Brain Research</i> , 2013, 1524, 62-73.	2.2	38
89	Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants. <i>Journal of Neuroscience Research</i> , 2012, 90, 2306-2316.	2.9	37
90	Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. <i>Acta Neuropathologica</i> , 2003, 106, 243-250.	7.7	36

#	ARTICLE	IF	CITATIONS
91	Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone. <i>Journal of Neurochemistry</i> , 2015, 135, 958-974.	3.9	35
92	Motor neuron loss and neuroinflammation in a model of α -synuclein-induced neurodegeneration. <i>Neurobiology of Disease</i> , 2018, 120, 98-106.	4.4	32
93	Transgenic Mice Expressing Human α -Synuclein in Noradrenergic Neurons Develop Locus Coeruleus Pathology and Nonmotor Features of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2020, 40, 7559-7576.	3.6	32
94	Comparative analyses of the in vivo induction and transmission of α -synuclein pathology in transgenic mice by MSA brain lysate and recombinant α -synuclein fibrils. <i>Acta Neuropathologica Communications</i> , 2019, 7, 80.	5.2	30
95	Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With α -Synuclein Inclusions. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2009, 68, 785-796.	1.7	29
96	Studies of lipopolysaccharide effects on the induction of α -synuclein pathology by exogenous fibrils in transgenic mice. <i>Molecular Neurodegeneration</i> , 2015, 10, 32.	10.8	29
97	Glucocerebrosidase haploinsufficiency in A53T α -synuclein mice impacts disease onset and course. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 198-208.	1.1	28
98	Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts. <i>Journal of Virology</i> , 2018, 92, .	3.4	28
99	Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease. <i>Acta Neuropathologica</i> , 2018, 136, 919-938.	7.7	27
100	The A53E α -synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture. <i>Neuroscience Letters</i> , 2015, 597, 43-48.	2.1	26
101	Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes. <i>Molecular Therapy</i> , 2021, 29, 859-872.	8.2	26
102	Phosphorylation of serine 305 in tau inhibits aggregation. <i>Neuroscience Letters</i> , 2019, 692, 187-192.	2.1	25
103	Robust cytoplasmic accumulation of phosphorylated TDP-43 in transgenic models of tauopathy. <i>Acta Neuropathologica</i> , 2013, 126, 39-50.	7.7	24
104	Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. <i>Human Molecular Genetics</i> , 2019, 28, 3255-3269.	2.9	24
105	Differential cross-seeding properties of tau and α -synuclein in mouse models of tauopathy and synucleinopathy. <i>Brain Communications</i> , 2020, 2, fcaa090.	3.3	24
106	Lack of evidence for Lrrk2 in α -synuclein pathological inclusions. <i>Annals of Neurology</i> , 2006, 60, 618-619.	5.3	23
107	Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations. <i>Journal of Biological Chemistry</i> , 2019, 294, 18488-18503.	3.4	23
108	Comparison of the in vivo induction and transmission of α -synuclein pathology by mutant α -synuclein fibril seeds in transgenic mice. <i>Human Molecular Genetics</i> , 2017, 26, 4906-4915.	2.9	22

#	ARTICLE	IF	CITATIONS
109	The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition. <i>Journal of Neurochemistry</i> , 2010, 115, 36-46.	3.9	19
110	Non-prion-type transmission in A53T $\hat{\pm}$ -synuclein transgenic mice: a normal component of spinal homogenates from naïve non-transgenic mice induces robust $\hat{\pm}$ -synuclein pathology. <i>Acta Neuropathologica</i> , 2016, 131, 151-154.	7.7	19
111	Role of Mitochondrial Dysfunction in Parkinson's Disease. <i>Drugs and Aging</i> , 2007, 24, 95-105.	2.7	18
112	Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2. <i>Journal of Neuroscience Research</i> , 2015, 93, 1567-1580.	2.9	18
113	Residue Glu83 plays a major role in negatively regulating $\hat{\pm}$ -synuclein amyloid formation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1415-1420.	2.1	17
114	The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. <i>PLoS ONE</i> , 2017, 12, e0184262.	2.5	15
115	Locomotor differences in mice expressing wild-type human $\hat{\pm}$ -synuclein. <i>Neurobiology of Aging</i> , 2018, 65, 140-148.	3.1	15
116	Dissecting $\hat{\pm}$ -synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis. <i>Laboratory Investigation</i> , 2019, 99, 982-992.	3.7	15
117	Carboxy-terminal truncations of mouse $\hat{\pm}$ -synuclein alter aggregation and prion-like seeding. <i>FEBS Letters</i> , 2020, 594, 1271-1283.	2.8	14
118	Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier "phenotypic variability in autosomal dominant Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 31.	5.2	14
119	$\hat{\pm}$ -Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability. <i>Npj Parkinson's Disease</i> , 2021, 7, 76.	5.3	14
120	Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau-microtubule interactions and inhibits aggregation. <i>Scientific Reports</i> , 2021, 11, 17069.	3.3	13
121	Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions. <i>Acta Neuropathologica</i> , 2021, 141, 359-381.	7.7	13
122	Transgenic mice expressing S129 phosphorylation mutations in $\hat{\pm}$ -synuclein. <i>Neuroscience Letters</i> , 2014, 563, 96-100.	2.1	12
123	Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. <i>PLoS ONE</i> , 2018, 13, e0195211.	2.5	12
124	Collusion of $\hat{\pm}$ -Synuclein and $\hat{\text{A}}^2$ aggravating co-morbidities in a novel prion-type mouse model. <i>Molecular Neurodegeneration</i> , 2021, 16, 63.	10.8	12
125	Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human $\hat{\pm}$ -synuclein transgenic mice. <i>Acta Neuropathologica</i> , 2022, 143, 663-685.	7.7	12
126	Partial loss of ATP13A2 causes selective gliosis independent of robust lipofuscinosis. <i>Molecular and Cellular Neurosciences</i> , 2018, 92, 17-26.	2.2	11

#	ARTICLE	IF	CITATIONS
127	Carboxy-terminal truncation and phosphorylation of $\hat{\pm}$ -synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy. <i>Neuroscience Letters</i> , 2020, 732, 135017.	2.1	11
128	Robust $\hat{\pm}$ -synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 80.	5.2	11
129	$\hat{\pm}$ -Synuclein Induces Progressive Changes in Brain Microstructure and Sensory-Evoked Brain Function That Precedes Locomotor Decline. <i>Journal of Neuroscience</i> , 2020, 40, 6649-6659.	3.6	10
130	Disease-, region- and cell type specific diversity of $\hat{\pm}$ -synuclein carboxy terminal truncations in synucleinopathies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 146.	5.2	10
131	Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	10
132	Inefficient induction and spread of seeded tau pathology in P301L mouse model of tauopathy suggests inherent physiological barriers to transmission. <i>Acta Neuropathologica</i> , 2015, 130, 303-305.	7.7	9
133	Fragile X-associated tremor ataxia syndrome with co-occurrent progressive supranuclear palsy-like neuropathology. <i>Acta Neuropathologica Communications</i> , 2019, 7, 158.	5.2	8
134	Generation and Characterization of Novel Monoclonal Antibodies Targeting $\hat{\pm}$ 62/sequestosome-1 Across Human Neurodegenerative Diseases. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2020, 79, 407-418.	1.7	8
135	Il-10 signaling reduces survival in mouse models of synucleinopathy. <i>Npj Parkinson's Disease</i> , 2021, 7, 30.	5.3	8
136	Combinatorial model of amyloid $\hat{\pm}$ 2 and tau reveals synergy between amyloid deposits and tangle formation. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	8
137	Adsorption and decontamination of $\hat{\pm}$ -synuclein from medically and environmentally-relevant surfaces. <i>Colloids and Surfaces B: Biointerfaces</i> , 2018, 166, 98-107.	5.0	7
138	An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes. <i>Journal of Experimental Medicine</i> , 2019, 216, 2479-2491.	8.5	7
139	Pathogenic MAPT mutations Q336H and Q336R have isoform-dependent differences in aggregation propensity and microtubule dysfunction. <i>Journal of Neurochemistry</i> , 2021, 158, 455-466.	3.9	7
140	Prodromal neuroinvasion of pathological $\hat{\pm}$ -synuclein in brainstem reticular nuclei and white matter lesions in a model of $\hat{\pm}$ -synucleinopathy. <i>Brain Communications</i> , 2021, 3, fcab104.	3.3	7
141	Targeted proteolytic products of $\hat{\pm}$, and $\hat{\pm}$ -synuclein in neurodegeneration. <i>Essays in Biochemistry</i> , 2021, 65, 905-912.	4.7	6
142	Does a prion-like mechanism play a major role in the apparent spread of $\hat{\pm}$ -synuclein pathology?. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 48.	6.2	5
143	Exploring the Peripheral Initiation of Parkinson's Disease in Animal Models. <i>Neuron</i> , 2019, 103, 547-549.	8.1	5
144	Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with $\hat{\pm}$ -synuclein inclusions. , 2004, , 353-375.		5

#	ARTICLE	IF	CITATIONS
145	Mitochondrial Injury: A Hot Spot for Parkinsonism and Parkinson's Disease?. Science of Aging Knowledge Environment: SAGE KE, 2004, 2004, pe42-pe42.	0.8	4
146	Pathogenic tau recruits wild-type tau into brain inclusions and induces gut degeneration in transgenic SPAM mice. Communications Biology, 2022, 5, 446.	4.4	4
147	Differential induction of mutant SOD1 misfolding and aggregation by tau and α -synuclein pathology. Molecular Neurodegeneration, 2018, 13, 23.	10.8	3
148	Novel monoclonal antibodies targeting the RRM2 domain of human TDP-43 protein. Neuroscience Letters, 2020, 738, 135353.	2.1	3
149	Prion-like transmission of α -synuclein pathology in the context of an NFL null background. Neuroscience Letters, 2017, 661, 114-120.	2.1	2
150	Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse $A\beta$ plaque pathology when injected into newborn mouse hosts.. Free Neuropathology, 2022, 3, .	3.0	2
151	Designing antibodies against LRRK2-targeted tau epitopes. PLoS ONE, 2018, 13, e0204367.	2.5	1
152	Novel SOD1 monoclonal antibodies against the electrostatic loop preferentially detect misfolded SOD1 aggregates. Neuroscience Letters, 2021, 742, 135553.	2.1	1
153	S4-02-03: Cell-to-cell transmission of synucleinopathy. , 2015, 11, P258-P258.		0